Evidence map›Paper›PMID 36168681›Full record

ArticleCancer reports (Hoboken, N.J.)2023

A SelectMDx/magnetic resonance imaging-based nomogram to diagnose prostate cancer.

Vinayak G Wagaskar, Micah Levy, Parita Ratnani, Sharmila Sullimada, Mae Gerenia, Kacie Schlussel, Samia Choudhury, Marla Gabriele, Ian Haas, Kenneth Haines and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Overdiagnosis and Overtreatment in Prostate Cancer.Diseases (Basel, Switzerland) · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Vinayak G WagaskarDepartment of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA.ORCID 0000-0001-8027-6661
Micah LevyDepartment of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA.
Parita RatnaniDepartment of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA.ORCID 0000-0002-4153-1014
Sharmila SullimadaDepartment of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA.
Mae GereniaDepartment of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA.
Kacie SchlusselDepartment of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA.
Samia ChoudhuryDepartment of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA.
Marla GabrieleDepartment of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA.
Ian HaasDepartment of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA.
Kenneth HainesDepartment of Pathology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA.
Ash TewariDepartment of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA.
Mount Sinai Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background70%-80% of prostate cancer (PCa) biopsies performed in the US annually may be unnecessary. Specific antigen testing (PSA) and tans rectal ultrasound (TRUS) are imprecise predictive methods for risk of PCa. Novel strategies are critical to guide biopsy decision-making.

aimWe assessed the utility and accuracy of combining Select MDx and multiparametric magnetic resonance imaging (mpMRI) scores for predicting risk of PCa. METHODS AND

resultsOur study was conducted at Mount Sinai hospital at Urology department in New York City from January 2020 to April 2021. Total 129 men performed select MDx test. Indications for prostate biopsy were high-risk Select MDx score, suspicious DRE, PI-RADS scores 3/4/5 on mpMRI, or any combination of these. Fifty-one percentage of 129 patients underwent systemic or combined systemic and MRI/US (ultrasound) fusion biopsy; All men underwent 3 T MRI of Prostate w/wo contrast using standard protocols prior to biopsy. A single surgeon performed prostate biopsies. Gleason score ≥3 + 3 on biopsy is defined as outcome. Descriptive statistics were calculated as cross tables. Binary logistic regression model is used to determine the outcome. The nomogram was based on the coefficients of the logit function. ROCs were plotted and decision curve analysis was performed. Using both high-risk Select MDx and PI-RADS scores of 4/5, 87% of biopsies could have been avoided, while detecting 64% of PCa and missing 36%. If biopsies were performed on men with positive Select MDx or PI-RADS 4/5 results, 16% of biopsies could have been avoided while detecting all PCa. Combining these scores improved specificity and accuracy for the detection of PCa over either used alone. Study limitations include limited sample size, sole institution study, and risk or overfitting for the proposed model which may limit generalizability.

conclusionCombining SelectMDx and mpMRI PI-PADS scores of 4/5 may be useful for PCa biopsy decision-making.

Indexed as

Prostatic NeoplasmsHumansImage-Guided BiopsyMagnetic Resonance ImagingMaleNomogramsProstatempMRI PI RADS scorePCa biomarkersprostate biopsySelectMDx

Identifiers

PMID36168681
PMCPMC9875685
OpenAlexW4297459308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.